Share on StockTwits

Cytomedix (NASDAQ:CMXI) CFO Steven A. Shallcross acquired 52,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was purchased at an average price of $0.39 per share, with a total value of $20,280.00. Following the purchase, the chief financial officer now directly owns 52,000 shares in the company, valued at approximately $20,280. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cytomedix (NASDAQ:CMXI) traded up 2.63% during mid-day trading on Monday, hitting $0.39. The stock had a trading volume of 15,000 shares. Cytomedix has a 52-week low of $0.33 and a 52-week high of $0.68. The stock’s 50-day moving average is $0.39 and its 200-day moving average is $0.47. The company’s market cap is $48.5 million.

Cytomedix, Inc is a United States-based company that develops biologically active regenerative therapies for wound and tissue repair.

Receive News & Ratings for Cytomedix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytomedix Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.